Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The RESET trial

Journal of Rheumatology

Volumn 38, Issue 12, 2011, Pages 2548-2556

  Haraoui, Boulos ^a   Bokarewa, Maria ^b   Kallmeyer, Ian ^c   Bykerk, Vivian P ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Hoffmann La Roche Ltd   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti CD20 antigen; Monoclonal antibody; Rheumatoid arthritis; Rituximab; Tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTHRALGIA; ARTICLE; BREAST CELLULITIS; BREAST DISEASE; BRONCHITIS; CANADA; CELLULITIS; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; INFUSION REACTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RETREATMENT; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SELF REPORT; SINUSITIS; SWEDEN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82755176118     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110444     Document Type: Article

References (21)

1. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, editors. Kelley's textbook of rheumatology. Philadelphia: WB Saunders Company; 2001.
2. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol Suppl 1989;79:67-96. (Pubitemid 20005118)
3. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF blocking agents: Findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36. (Pubitemid 40740207)
4. Burmester GR, Monteagudo I, Saez I, Malaise MG, Canas da Silva J, Webber DG, et al. Adalimumab (Humira®) is effective in patients who have previously been treated with TNF antagonists (etanercept and/or infliximab) in widespread clinical practice: 12 week outcomes in the REACT trial. Ann Rheum Dis 2005;64 Suppl 3:423.
5. Emery P, Keystone E, Tony H-P, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomised placebo controlled trial. Ann Rheum Dis 2008;67;1516-23.
6. Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor á inhibition. N Engl J Med 2005;353:1114-23. (Pubitemid 41317434)
7. Smolen J, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
8. Rituxan (rituximab) product monograph. Hoffmann-La Roche Canada Ltd. June 2010.
9. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
10. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 2006;54:1390-400.
11. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay J-L, Carreno L, Armstrong G, et al., on behalf of the MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology 2010;49:1683-93.
12. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomized, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders; SERENE). Ann Rheum Dis 2010;69:1629-35.
13. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al.; for the IMAGE Investigators. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
14. Cohen SB, Emery P, Greenwald MW, Dougados MR, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
15. van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleishmann RM, Furst DE, et al. Long-term safety of rituximab: follow-up of the RA clinical trials and retreatment population. Ann Rheum Dis 2010;69 Suppl 3:66.
16. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon K, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. An open-label extension analysis. Arthritis Rheum 2007;56:3896-908. (Pubitemid 350262316)
17. Keystone EC, Fleischmann RM, Emery P, Dougados M, Williams S, Linnik MD, et al. Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors [abstract]. Arthritis Rheum 2010;62 Suppl:S133.
18. Guidance for industry clinical safety data management. Definitions and standards for expedited reporting, ICH Topic E2A. Health Canada. [Internet. Accessed Aug 18, 2011.] Available from: http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-ld/ich/efficac/e2a-eng.php
19. Cohen S, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158-61.
20. Isaacs JD, Olech E, Tak PP, Deodhar A, Keystone E, Emery P, et al. Autoantibody-positive rheumatoid arthritis patients have enhanced clinical response to rituximab when compared with seronegative patients [abstract]. European League Against Rheumatism 2009 Annual European Congress of Rheumatology; Rome, Italy. Abstract 0256.
21. Mariette X, Kivitz A, Isaacs J, Stohl W, Tak PP, Jones R, et al. Effectiveness of rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes [abstract]. Arthritis Rheum 2009;60 Suppl:1687.